Sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents ejection fraction reduction, reduces myocardial and renal NF-κB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity.

Details

Language :

English

ISSN :

2297055X

Database :

Complementary Index

Journal :

Frontiers in Cardiovascular Medicine

Publication Type :

Academic Journal

Accession number :

177620016

Full Text :

https://doi.org/10.3389/fcvm.2024.1289663